🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 55 of 151

  1. GLPG0634

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  2. GLPG0974

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  3. GLPG1205

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  4. GLPG1205

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  5. GLPG1690

    Lakefront Biotherapeutics NV

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  6. GLPG1690 600 mg QD

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  7. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  8. GLPG1972

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  9. GLPG2222 150 mg q.d.

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  10. GLPG2222 50 mg

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  11. GLPG2737

    Lakefront Biotherapeutics NV

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  12. GLPG2737

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  13. GLPG3667

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  14. GLPG3667

    Lakefront Biotherapeutics NV

    Dermatomyositis

    phase 2 small molecule completed

    1 trial

  15. GLPG3970

    Lakefront Biotherapeutics NV

    Primary Sjögren Syndrome

    phase 2 small molecule terminated

    1 trial

  16. GLPG3970

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  17. GLPG3970

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  18. GLPG5101

    Lakefront Biotherapeutics NV

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 gene therapy active

    1 trial

  19. GLS-5300

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 2 mab completed

    2 trials

  20. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis B

    phase 2 small molecule completed

    3 trials

  21. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HBV Infection

    phase 2 small molecule completed

    1 trial

  22. GLUCOSE 5 % B.BRAUN, solution pour perfusion, ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  23. GLUT1 DS

    Ultragenyx UK Limited

    Glut1 Deficiency Syndrome

    phase 2 small molecule completed

    1 trial

  24. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    2 trials

  25. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Cancer of the Bile Duct

    phase 2 small molecule terminated

    1 trial

  26. GM-CT-01 plus 5-Fluorouracil

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  27. GPC-100

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  28. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial

  29. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  30. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Hypertension, Portal

    phase 2 small molecule completed

    1 trial

  31. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  32. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  33. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  34. GS-4321 PLACEBO

    Gilead Sciences Pty Limited

    Chronic Hepatitis Delta.

    phase 2 small molecule active

    1 trial

  35. GS030-DP, GS030-DP, GS030-DP

    GenSight Biologics S.A.

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  36. GSBR-1290

    Structure Therapeutics

    Overweight or Obesity

    phase 2 small molecule completed

    1 trial

  37. GSK Biologicals' GSK2340274A (two different formulations)

    GlaxoSmithKline

    Influenza

    phase 2 mab completed

    1 trial

  38. GSK influenza virus H5N1 vaccine 1557484A

    United Therapeutics Europe Ltd

    Influenza

    phase 2 mab terminated

    1 trial

  39. GSK1070806

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule terminated

    1 trial

  40. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  41. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  42. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  43. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  44. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  45. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  46. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  47. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  48. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.